Transaction DateRecipientSharesTypePriceValue
17th November 2020Ferreira Juan Camilo Arjona7,000Exercise of derivative$7.78$54,460.00
17th November 2020Ferreira Juan Camilo Arjona7,000Open or private sale$20.00$140,000.00
17th November 2020Frank Karbe750Open or private sale$20.00$15,000.00
17th November 2020Frank Karbe750Exercise of derivative$5.11$3,832.50
13th November 2020Ferreira Juan Camilo Arjona7,000Open or private sale$20.00$140,000.00
13th November 2020Ferreira Juan Camilo Arjona7,000Exercise of derivative$7.78$54,460.00
11th November 2020Global Performance Llc Viking2,500,000Open or private sale$49.52$123,787,500.00
11th November 2020Global Investors Lp Viking2,500,000Open or private sale$49.52$123,787,500.00
22nd October 2020Kathleen Sebelius420Grant/award etc.$0.00
17th September 2020Sciences Ltd. Roivant8,773,969Other acquisition or disposition$0.00
Myovant Sciences Ltd.
Myovant Sciences Ltd. logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company was founded on February 2, 2016 and is headquartered in London.


Ticker: MYOV
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1679082
Employees: 167
Exchange: New York Stock Exchange
Auditor Opinion:Going Concern

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $85 M (0%)
Marketable Securities, Current: $15 M (399%)
Assets, Current: $109 M (24%)
Property, Plant and Equipment, Net: $2 M (-1%)
Other Assets, Noncurrent: $4 M (0%)
Assets: $127 M (19%)
Accounts Payable, Current: $5 M (-64%)
Accrued Liabilities, Current: $29 M (0%)
Liabilities, Current: $53 M (-38%)
Other Liabilities, Noncurrent: $4 M (23%)
Liabilities: $261 M (21%)
Common Stock, Value, Issued: $2 Th (0%)
Common Stock, Shares, Issued: $90 M (0%)
Retained Earnings (Accumulated Deficit): $824 M (4%)
Stockholders' Equity (Parent): $135 M (0%)
Liabilities and Equity: $127 M (19%)
Research and Development: $44 M (-13%)
General and Administrative Expenses: $23 M (61%)
Operating Income/Loss: $34 M (-48%)
Provision for income taxes: $672 Th (114%)